Insuman Comb 15/85

Insuman Comb 15/85: Insulin of combined duration of action

Insulin is a key drug for controlling blood sugar levels in patients with diabetes. One of these drugs is Insuman Comb 15/85, which belongs to the group of insulins with a combined duration of action. In this article we will look at the main characteristics, manufacturer and dosage forms of this drug.

Insuman Comb 15/85 is manufactured in Germany by Hoechst AG. It is available in the form of an injectable suspension containing 40 units of insulin per milliliter. There is also an injection suspension option with a concentration of 100 units of insulin per milliliter.

This drug belongs to the group of insulins with a combined duration of action. It consists of a combination of two types of insulin: 15% fast-acting insulin and 85% intermediate-acting insulin. This combination provides more stable blood glucose control over the long term.

Insuman Comb 15/85 has several synonyms, including Actrafan HM penfil 100, Berlinsulin N 10/90 U-40, Berlinsulin N 10/90 pen, Berlinsulin N 20/80 U-40, Berlinsulin N 20/80 pen, Berlinsulin N 30 /70 U-40, Berlinsulin N 30/70 pen, Berlinsulin N 40/60 U-40, Berlinsulin N 40/60 pen, Biogulin 30/70 U-100 and Insul.

Patients suffering from diabetes usually receive dosage recommendations for Insuman Comb 15/85 from their doctor based on individual characteristics and needs. Insulin is usually injected subcutaneously before meals.

It is important to note that the use of Insuman Comb 15/85 may be accompanied by some side effects, such as hypoglycemia (low blood sugar), hyperglycemia (high blood sugar), allergic reactions and injection site problems. Patients should be alert and seek medical attention if adverse effects occur.

In conclusion, Insuman Comb 15/85 is a long-acting insulin designed to control blood sugar levels in patients with diabetes. It is manufactured in Germany by Hoechst AG and is available in the form of an injection suspension with different insulin concentrations. The combination of fast-acting and intermediate-acting insulin provides stable control of blood glucose levels. Patients should follow their doctor's recommendations and be alert to possible side effects.